Feasibility of reduced-intensity allogeneic stem cell transplantation with imatinib in children with philadelphia chromosome-positive acute lymphoblastic leukemia†
Corresponding Author
Kayo Yamada MD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Correspondence to: Kayo Yamada, Department of Hematology/Oncology, Osaka Medical Center and Research, Institute for Maternal and Child Health, 840 Murodo-Cho, Izumi, Osaka 594-1101, Japan.
E-mail: [email protected]
Search for more papers by this authorMasahiro Yasui MD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Search for more papers by this authorOsamu Kondo MD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Search for more papers by this authorMaho Sato MD, PhD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Search for more papers by this authorAkihisa Sawada MD, PhD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Search for more papers by this authorKeisei Kawa MD, PhD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Search for more papers by this authorMasami Inoue MD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Search for more papers by this authorCorresponding Author
Kayo Yamada MD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Correspondence to: Kayo Yamada, Department of Hematology/Oncology, Osaka Medical Center and Research, Institute for Maternal and Child Health, 840 Murodo-Cho, Izumi, Osaka 594-1101, Japan.
E-mail: [email protected]
Search for more papers by this authorMasahiro Yasui MD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Search for more papers by this authorOsamu Kondo MD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Search for more papers by this authorMaho Sato MD, PhD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Search for more papers by this authorAkihisa Sawada MD, PhD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Search for more papers by this authorKeisei Kawa MD, PhD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Search for more papers by this authorMasami Inoue MD
Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi City, Osaka, Japan
Search for more papers by this authorAbstract
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) in children is one of the highest-risk ALL groups. Improved outcome in combination with imatinib has been reported. However, intensive chemotherapy or myeloablative conditioning followed by hematopoietic stem cell transplantation (HSCT) can be associated with significant adverse late effects. We report a case series of five children with Ph + ALL underwent reduced-intensity allogeneic HSCT (RIST) after induction and consolidation in chemotherapy combined with imatinib. Four of the five patients remain first complete remission for a median of 3.1 years after RIST. These results are preliminary, but suggest the feasibility and effectiveness of RIST with imatinib. Pediatr Blood Cancer 2013;60:E60–E62. © 2013 Wiley Periodicals, Inc.
REFERENCES
- 1 Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998–1006.
- 2 Aricò M, Schrappe M, Hunger SP, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 2010; 28: 4755–4761.
- 3 Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL). Blood 2006; 108: 1469–1477.
- 4 Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105: 3449–3457.
- 5 Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group Study. J Clin Oncol 2009; 27: 5175–5181.
- 6 Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study. Lancet Oncol 2012; 13: 936–945.
- 7 Rives S, Estella J, Gómez P, et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): Results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol 2011; 154: 600–611.
- 8 Shimizu M, Sawada A, Yamada K, et al. Encouraging results of preserving ovarian function after allo-HSCT with RIC. Bone Marrow Transplant 2012; 47: 141–142.
- 9 Sawada A, Sakata N, Kishimoto T, et al. Significance of four MRD markers in MRD-based treatment strategy for childhood acute lymphoblastic leukemia. Leuk Res 2009; 33: 1710–1713.
- 10 Suzuki N, Yumura-Yagi K, Yoshida M, et al. Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol. Pediatr Blood Cancer 2010; 54: 71–78.
- 11 Yamada K, Yasui M, Sawada A, et al. Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain. Pediatr Blood Cancer 2012; 58: 300–302.
- 12 Schultz KR, Prestidge T, Camitta B. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: New and emerging treatment options. Expert Rev Hematol 2010; 3: 731–742.
- 13 Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 348–371.
- 14 Satwani P, Morris E, Bradley MB, et al. Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases. Pediatr Blood Cancer 2008; 50: 1–8.
- 15 Inoue M, Okamura T, Yasui M, et al. Increased intensity of acute graft-versus-host disease after reduced-intensity bone marrow transplantation compared to conventional transplantation from an HLA-matched sibling in children. Bone Marrow Transplant 2006; 37: 601–605.
- 16 Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010; 85: 387–398.
- 17 Larmonier N, Janikashvili N, LaCasse CJ, et al. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL-tumors. J Immunol 2008; 181: 6955–6963.
- 18 Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol 2009; 89: 251–252.
- 19 Porkka K, Koskenvesa P, Lundán T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008; 112: 1005–1012.
- 20 Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009; 27: 469–471.
